No Data
Protara Therapeutics Announces 6-Month Data From ADVANCED-2 Trial; Expects New Data Mid-2025, Begins Dosing In THRIVE-3 Trial In H1 2025, Awaits Results For STARBORN-1 Trial By End Of H1 2025.
Protara Highlights Recent Updates and Anticipated 2025 Milestones
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Protara Therapeutics Closes $100 Million Securities Offering
Protara Therapeutics 13.69M Share Spot Secondary Priced at $6.25
Protara: Gross Proceeds From Offering Expected to Be Approximately $100M >TARA